ValuEngine cut shares of Alpine Immune Sciences (NASDAQ:ALPN) from a hold rating to a sell rating in a research note issued to investors on Thursday.
A number of other research analysts also recently commented on the company. Piper Jaffray Companies initiated coverage on Alpine Immune Sciences in a report on Thursday, September 27th. They set an overweight rating and a $12.00 target price on the stock. Zacks Investment Research downgraded Alpine Immune Sciences from a hold rating to a sell rating in a report on Tuesday, October 16th. Finally, Raymond James initiated coverage on Alpine Immune Sciences in a report on Monday, August 13th. They set a buy rating and a $13.00 target price on the stock. Two research analysts have rated the stock with a sell rating and five have given a buy rating to the company’s stock. The stock has an average rating of Hold and a consensus target price of $12.67.
NASDAQ:ALPN traded down $0.23 during trading hours on Thursday, reaching $4.77. 3,700 shares of the stock were exchanged, compared to its average volume of 18,038. The company has a quick ratio of 20.99, a current ratio of 20.99 and a debt-to-equity ratio of 0.05. Alpine Immune Sciences has a 52 week low of $4.61 and a 52 week high of $11.75. The company has a market cap of $64.11 million, a PE ratio of -3.98 and a beta of 0.54.
Alpine Immune Sciences (NASDAQ:ALPN) last released its earnings results on Thursday, August 9th. The biotechnology company reported ($0.57) EPS for the quarter, missing analysts’ consensus estimates of ($0.44) by ($0.13). Alpine Immune Sciences had a negative return on equity of 26.00% and a negative net margin of 1,602.19%. The firm had revenue of $0.39 million for the quarter, compared to the consensus estimate of $0.30 million. As a group, sell-side analysts expect that Alpine Immune Sciences will post -2.12 EPS for the current fiscal year.
Large investors have recently added to or reduced their stakes in the business. Renaissance Technologies LLC raised its position in shares of Alpine Immune Sciences by 20.9% during the 2nd quarter. Renaissance Technologies LLC now owns 122,424 shares of the biotechnology company’s stock worth $927,000 after purchasing an additional 21,124 shares during the period. Dimensional Fund Advisors LP raised its position in shares of Alpine Immune Sciences by 122.2% during the 2nd quarter. Dimensional Fund Advisors LP now owns 32,819 shares of the biotechnology company’s stock worth $248,000 after purchasing an additional 18,052 shares during the period. Finally, DRW Securities LLC raised its position in shares of Alpine Immune Sciences by 138.7% during the 2nd quarter. DRW Securities LLC now owns 24,343 shares of the biotechnology company’s stock worth $184,000 after purchasing an additional 14,143 shares during the period. 56.87% of the stock is currently owned by institutional investors.
About Alpine Immune Sciences
Alpine Immune Sciences, Inc focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, inflammatory disorders, and other diseases. Its lead programs include ALPN-101, an ICOS/CD28 antagonist program for the treatment of autoimmune and inflammatory diseases; and ALPN-202 program for the treatment of cancer.
Featured Story: Balanced Fund
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Alpine Immune Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alpine Immune Sciences and related companies with MarketBeat.com's FREE daily email newsletter.